GeoVax Advances Mpox Vaccine Development Amid Global Outbreak Concerns

GeoVax Labs, Inc. has highlighted the critical need for expanding global access to Mpox vaccines, as recent outbreaks and rising transmission rates of Clade I and Clade II Mpox underscore the urgency for diversified vaccine supplies. The European Medicines Agency (EMA) has endorsed a streamlined development pathway for GeoVax's GEO-MVA vaccine candidate, allowing for a single Phase 3 immuno-bridging trial to support a Marketing Authorisation Application (MAA). This approach aims to reduce development time while maintaining regulatory standards, offering a quicker route to vaccine availability.

The global spread of Clade I Mpox, with cases now reported across all continents, including China, the United Kingdom, Italy, and the U.S., has raised significant public health concerns. The detection of local transmission in China and travel-linked cases from Ethiopia and the Democratic Republic of the Congo (DRC) to G7 countries highlights the high risk of international spread. Additionally, new data confirming vertical transmission of Mpox from mother to child during pregnancy in the DRC has intensified calls for next-generation vaccines with comprehensive safety profiles and broader availability.

GeoVax's GEO-MVA vaccine is being developed as a scalable, strategic alternative to existing MVA-based vaccines, with plans to transition to a modernized manufacturing system for lower-cost, U.S.-based production. The company is engaging with global health organizations and governments to facilitate rapid deployment of GEO-MVA in response to current and emerging Mpox hotspots, addressing the immediate need for vaccine diversification and long-term infrastructure resilience.